EDSA
Edesa Biotech, Inc. NASDAQ Listed Jun 21, 2010$4.60
Mkt Cap $44.3M
52w Low $0.72
19.8% of range
52w High $20.32
50d MA $6.10
200d MA $5.19
P/E (TTM)
—
EV/EBITDA
—
P/B
2.1x
Debt/Equity
0.0x
ROE
-56.0%
P/FCF
-3.6x
RSI (14)
40.10
ATR (14)
$0.63
Beta
-0.68
50d MA
$6.10
200d MA
$5.19
Avg Volume
85.4K
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
100 Spy Court · Markham, ON L3R 5H6 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | AMC | -0.44 | -0.60 | -36.4% | 5.43 | +4.8% | -1.5% | +5.6% | +1.1% | +0.7% | -17.2% | — |
| May 14, 2026 | AMC | -0.24 | -0.49 | -104.2% | 14.61 | +0.0% | -10.7% | -31.0% | +32.8% | -8.5% | -0.5% | — |
| Feb 13, 2026 | AMC | -0.28 | -0.28 | +0.0% | 1.02 | +10.8% | +0.0% | -2.7% | -9.0% | -11.4% | +12.4% | — |
| Dec 12, 2025 | AMC | -0.27 | -0.32 | -18.5% | 1.74 | -2.9% | -16.1% | +2.1% | +2.0% | -3.3% | +0.7% | — |
| Aug 8, 2025 | AMC | -0.26 | -0.25 | +3.8% | 2.12 | -0.9% | -0.5% | +2.8% | +0.9% | +3.2% | -0.9% | — |
| May 14, 2025 | AMC | -0.30 | -0.30 | +0.0% | 2.03 | -1.5% | -1.5% | +1.5% | -1.0% | +1.0% | -1.5% | — |
| Feb 14, 2025 | AMC | -0.31 | -0.48 | -54.8% | 2.69 | -14.5% | -7.1% | +1.6% | -1.6% | -2.8% | -7.8% | — |
| Dec 13, 2024 | AMC | -0.54 | -0.29 | +46.3% | 1.94 | -3.1% | -2.1% | -1.6% | -2.7% | -3.8% | -1.1% | — |
| Aug 9, 2024 | AMC | -0.58 | -0.52 | +10.3% | 4.84 | -5.0% | -4.8% | -1.7% | -0.9% | -3.8% | +1.4% | — |
| May 10, 2024 | AMC | -0.69 | -0.58 | +15.9% | 4.61 | +0.0% | -3.9% | +2.3% | -0.4% | +0.2% | +0.7% | — |
| Feb 9, 2024 | AMC | -1.21 | -0.54 | +55.4% | 4.83 | +5.2% | +7.9% | -4.0% | +13.4% | -0.4% | -5.0% | — |
| Dec 15, 2023 | AMC | -0.71 | -0.60 | +15.5% | 5.19 | -8.3% | -7.5% | +3.8% | -2.2% | -1.0% | +4.6% | — |
| Aug 9, 2023 | AMC | -1.19 | -0.70 | +41.2% | 6.44 | +4.3% | -3.3% | +0.0% | -2.2% | -2.3% | -1.2% | — |
| May 11, 2023 | AMC | -1.19 | -0.84 | +29.4% | 6.65 | +4.2% | -7.4% | +0.0% | -3.4% | +10.6% | -3.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.86 | $1.80 | -3.2% | -6.5% | -2.3% | -0.6% | +0.6% | +0.6% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.38 | $2.49 | +4.6% | +0.0% | +0.4% | +2.1% | -2.5% | +3.4% |
| Nov 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.15 | $3.25 | +3.2% | +5.1% | -0.3% | +4.5% | -2.0% | +3.6% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.80 | $3.13 | +11.8% | +12.9% | +2.8% | -3.4% | +0.3% | +5.1% |
| Oct 12 | Brookline Capital | Maintains | Buy → Buy | — | $2.70 | $3.00 | +11.1% | +80.7% | -18.9% | +6.8% | -2.6% | -0.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.09 | $6.02 | -1.1% | -2.3% | -1.2% | +1.2% | +2.4% | -2.3% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.23 | $6.02 | -3.4% | -2.2% | -2.3% | -1.2% | +1.2% | +2.4% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.44 | $6.44 | +0.0% | +7.6% | -9.1% | +1.1% | -1.1% | +1.1% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.37 | $6.44 | +1.1% | +1.1% | +7.6% | -9.1% | +1.1% | -1.1% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.75 | $8.47 | -3.2% | -4.0% | +2.5% | -19.5% | +9.1% | -3.7% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.80 | $9.87 | +0.7% | -0.7% | +3.6% | +2.1% | -2.7% | +2.8% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.97 | $42.98 | +7.5% | -0.4% | +2.3% | +5.2% | +5.7% | -5.9% |
No insider trades available.
8-K · 3.02
!! High
Edesa Biotech, Inc. -- 8-K 3.02: Unregistered Securities Offering
Jun 11
8-K · 8.01
!! High
Edesa Biotech, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 5
8-K · 5.02
!!! Very High
Edesa Biotech, Inc. -- 8-K 5.02: Executive Change
May 15
8-K · 8.01
!! High
Edesa Biotech, Inc. Common Shares -- 8-K 8.01: Material Event / Announcement
Edesa Biotech's anti-TLR4 antibody showed statistically significant 28-day mortality reduction across 278 patients, expanding positive data beyond the previously reported invasive mechanical ventilation subset.
Feb 24
8-K
Edesa Biotech, Inc. Common Shares -- 8-K Filing
Edesa Biotech advanced EB06 manufacturing for its Phase 2 vitiligo trial, signaling progress toward potential commercialization in dermatology immunology treatment.
Feb 13
Valuation
Market Cap
$44.3M
Enterprise Value
$15.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.06x
P/B
2.10x
P/S
—
P/FCF
-3.57x
EV/EBITDA
—
Shares Out
5.7M
Financials (TTM)
Revenue
$0
Net Income
-$14.1M
EBITDA
-$14.3M
Free Cash Flow
-$7.3M
Op Cash Flow
-$7.3M
EPS Basic
$-1.27
EPS Diluted
$-1.69
EPS Forward
$-1.64
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$13.5M
Total Liab.
$1.1M
Total Equity
$12.5M
Cash
$10.8M
LT Debt
$0
Book Value/Sh
$2.19
Debt/Equity
0.00x
Current Ratio
10.67
Quick Ratio
10.67
Returns & Growth
ROE
-56.0%
ROA
-53.1%
ROIC
-63.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
+34.2%
Price Returns
2W
-15.3%
1M
-14.0%
3M
-42.3%
6M
+109.1%
12M
+91.7%
Technicals
52W High
$20.32
52W Low
$0.72
50d MA
$6.10
200d MA
$5.19
RSI (14)
40.10
ATR (14)
$0.63
Beta
-0.68
Avg Volume
85K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 6:27am
· Source: financialmodelingprep.com